May 14, 2012
Keryx Biopharmaceuticals moved north as they received positive result from Japan on Zerenex. Even after the late-week run of KERX shares, this stock still may have significant room left to move to the upside, especially during the lead-in to Zerenex Phase III results, which are due out later this year. Investers should note that Keryx [...]
Read the full article →
September 28, 2011
A startup Biotech company is evaluated primarily by products in the pipeline. GERN’s current well publicized trial is dealing with using stem cells to treat patients with spinal cord injuries so they can regain mobility. Don’t get me wrong, if GERN is successful with their stem cell technology it will be a game changer for [...]
Read the full article →